School of Life Sciences, DA University, Indore, India.
Immunology. 2010 Apr;129(4):482-95. doi: 10.1111/j.1365-2567.2009.03200.x. Epub 2009 Dec 2.
The lectin pathway of complement is activated upon binding of mannan-binding lectin (MBL) or ficolins (FCNs) to their targets. Upon recognition of targets, the MBL-and FCN-associated serine proteases (MASPs) are activated, allowing them to generate the C3 convertase C4b2a. Recent findings indicate that the MASPs also activate components of the coagulation system. We have previously shown that MASP-1 has thrombin-like activity whereby it cleaves and activates fibrinogen and factor XIII. MASP-2 has factor Xa-like activity and activates prothrombin through cleavage to form thrombin. We now report that purified L-FCN-MASPs complexes, bound from serum to N-acetylcysteine-Sepharose, or MBL-MASPs complexes, bound to mannan-agarose, generate clots when incubated with calcified plasma or purified fibrinogen and factor XIII. Plasmin digestion of the clot and analysis using anti-D-dimer antibodies revealed that the clot was made up of fibrin and was similar to that generated by thrombin in normal human plasma. Fibrinopeptides A and B (FPA and FPB, respectively) were released after fibrinogen cleavage by L-FCN-MASPs complexes captured on N-acetylcysteine-Sepharose. Studies of inhibition of fibrinopeptide release indicated that the dominant pathway for clotting catalysed by the MASPs is via MASP-2 and prothrombin activation, as hirudin, a thrombin inhibitor that does not inhibit MASP-1 and MASP-2, substantially inhibits fibrinopeptide release. In the light of their potent chemoattractant effects on neutrophil and fibroblast recruitment, the MASP-mediated release of FPA and FPB may play a role in early immune activation. Additionally, MASP-catalysed deposition and polymerization of fibrin on the surface of micro-organisms may be protective by limiting the dissemination of infection.
补体的凝集素途径在甘露聚糖结合凝集素(MBL)或纤维胶凝蛋白(FCNs)与其靶标结合时被激活。在识别靶标后,MBL 和 FCN 相关丝氨酸蛋白酶(MASPs)被激活,使它们能够生成 C3 转化酶 C4b2a。最近的研究结果表明,MASPs 还能激活凝血系统的成分。我们之前已经表明,MASP-1 具有类凝血酶活性,可通过切割和激活纤维蛋白原和因子 XIII。MASP-2 具有因子 Xa 样活性,并通过切割形成凝血酶激活凝血酶原。我们现在报告说,从血清中结合到 N-乙酰半胱氨酸-琼脂糖上的 L-FCN-MASPs 复合物,或结合到甘露聚糖-琼脂糖上的 MBL-MASPs 复合物,在与钙化血浆或纯化的纤维蛋白原和因子 XIII 孵育时会产生凝块。用纤溶酶消化凝块并使用抗 D-二聚体抗体进行分析表明,凝块由纤维蛋白组成,与正常人类血浆中由凝血酶产生的凝块相似。纤维蛋白肽 A 和 B(分别为 FPA 和 FPB)在纤维蛋白原被 L-FCN-MASPs 复合物切割后被释放。纤维蛋白肽释放的抑制研究表明,MASPs 催化的凝血的主要途径是通过 MASP-2 和凝血酶原激活,因为水蛭素是一种不抑制 MASP-1 和 MASP-2 的凝血酶抑制剂,可显著抑制纤维蛋白肽的释放。鉴于它们对中性粒细胞和成纤维细胞募集的强烈趋化作用,MASP 介导的 FPA 和 FPB 的释放可能在早期免疫激活中发挥作用。此外,MASP 催化的纤维蛋白在微生物表面的沉积和聚合可能通过限制感染的传播而具有保护作用。